Captopril enhances insulin responsiveness of forearm muscle tissue in non‐insulin‐dependent diabetes mellitus

Jauch, Karl Walter; Hartl, Wolfgang H.; Guenther, B.; Wicklmayr, M.; Rett, K.; Dietze, G.

doi:10.1111/j.1365-2362.1987.tb01141.x

Cited by 143 publications

(70 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to the amelioration of insulin secretion through the increased islet blood flow induced by an ACE inhibitor, as seen in this study, the blockade of the RAS during the development of diabetes has been attributed to improvements in peripheral insulin sensitivity and b-cell dysfunction (30,31). ACE inhibitors have been shown to improve whole-body and skeletal muscle insulin resistance in hypertensive subjects with or without type 2 diabetes (32)(33)(34)(35)(36)(37)(38)(39)(40). The reduction of angiotensin II-mediated vascular resistance by ACE inhibition may improve insulin-stimulated glucose transport activity in skeletal muscle (41).…”

Section: Discussionmentioning

confidence: 86%

Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin Secretion

et al. 2014

View full text Add to dashboard Cite

Endothelial cells are considered to be essential for normal pancreatic β-cell function. The current study attempted to demonstrate the role of insulin receptor substrate-2 (Irs2) in endothelial cells with regard to insulin secretion. Endothelial cell–specific Irs2 knockout (ETIrs2KO) mice exhibited impaired glucose-induced, arginine-induced, and glucagon-induced insulin secretion and showed glucose intolerance. In batch incubation and perifusion experiments using isolated islets, glucose-induced insulin secretion was not significantly different between the control and the ETIrs2KO mice. In contrast, in perfusion experiments, glucose-induced insulin secretion was significantly impaired in the ETIrs2KO mice. The islet blood flow was significantly impaired in the ETIrs2KO mice. After the treatment of these knockout mice with enalapril maleate, which improved the islet blood flow, glucose-stimulated insulin secretion was almost completely restored to levels equal to those in the control mice. These data suggest that Irs2 deletion in endothelial cells leads to a decreased islet blood flow, which may cause impaired glucose-induced insulin secretion. Thus, Irs2 in endothelial cells may serve as a novel therapeutic target for preventing and ameliorating type 2 diabetes and metabolic syndrome.

show abstract

Section: Discussionmentioning

confidence: 86%

Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin Secretion

et al. 2014

View full text Add to dashboard Cite

show abstract

“…2). Increased activity of the renin angiotensin system has been associated with obesity and glucose intolerance, and prospective epidemiological studies have reported that blocking the system using either ACE inhibitors or ARBs has been shown to reduce the incidence of diabetes (27,28,29,30) and both ACE-inhibitors and ARBs may improve insulin action to different extents (31,32) as well as insulin secretion (33). Accordingly, it may be considered biologically plausible that bioactive peptides in the Cardi04 yogurt inhibiting ACE may reduce plasma glucose levels in patients with diabetes.…”

Section: Discussionmentioning

confidence: 99%

Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study

Hove

Brøns

Færch

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Studies have indicated a blood pressure (BP)-lowering effect of milk-derived peptides in non-diabetic individuals, but the cardiometabolic effects of such peptides in patients with type 2 diabetes (T2D) are not known. We investigated the effect of milk fermented with Lactobacillus helveticus on BP, glycaemic control and cardiovascular risk factors in T2D. Design: A randomised, double-blinded, prospective, placebo-controlled study. Methods: In one arm of a factorial study design, 41 patients with T2D were randomised to receive 300 ml milk fermented with L. helveticus (Cardi04 yogurt) (nZ23) or 300 ml artificially acidified milk (placebo yogurt) (nZ18) for 12 weeks. BPs were measured over 24-h, and blood samples were collected in the fasting state and during a meal test before and after the intervention. Results: Cardi04 yogurt did not reduce 24-h, daytime or nighttime systolic or diastolic BPs compared with placebo (PO0.05). Daytime and 24-h heart rate (HR) were significantly reduced in the group treated by Cardi04 yogurt compared with the placebo group (P!0.05 for both). There were no differences in HbA1c, plasma lipids, C-reactive protein, plasminogen activator inhibitor-1, tumour necrosis factor alpha, tissue-type plasminogen activator: Ag, and von Willebrand factor: Ag between the groups. The change in fasting blood glucose concentration differed significantly between the two groups with a larger increase in the placebo group (P!0.05). Conclusions: Ingestion of milk fermented with L. helveticus compared with placebo for 12 weeks did not significantly reduce BP in patients with T2D. Our finding of lower HRs and fasting plasma glucose levels in T2D patients during ingestion of fermented milk needs further validation.

show abstract

“…In clinical practice, the beneficial effects of the use of ACEi and AT 1 blockers in patients with type 2 diabetes has been known for quite some time [43][44][45]. The overactivity of the RAS is likely to impair insulin signaling and contribute to the insulin resistance observed in essential hypertension [7].…”

Section: The Cross-talk At the Extracellular Levelmentioning

confidence: 99%

The multi‐faceted cross‐talk between the insulin and angiotensin II signaling systems

Velloso

Folli

Perego

et al. 2006

Diabetes Metabolism Res

103

View full text Add to dashboard Cite

SummaryInsulin and angiotensin II are hormones that play pivotal roles in the control of two vital and closely related systems, the metabolic and the circulatory systems, respectively. A failure in the proper action of each of these hormones results, to a variable degree, in the development of two highly prevalent and commonly overlapping diseases -diabetes mellitus and hypertension. In recent years, a series of studies has revealed a tight connection between the signal transduction pathways that mediate insulin and angiotensin II actions in target tissues. This molecular cross-talk occurs at multiple levels and plays an important role in phenomena that range from the action of anti-hypertensive drugs to cardiac hypertrophy and energy acquisition by the heart. At the extracellular level, the angiotensin-converting enzyme controls angiotensin II synthesis but also interferes with insulin signaling through the proper regulation of angiotensin II and through the accumulation of bradykinin. At an early intracellular level, angiotensin II, acting through JAK-2/IRS-1/PI3-kinase, JNK and ERK, may induce the serine phosphorylation and inhibition of key elements of the insulin-signaling pathway. Finally, by inducing the expression of the regulatory protein SOCS-3, angiotensin II may impose a late control on the insulin signal. This review will focus on the main advances obtained in this field and will discuss the implications of this molecular cross-talk in the common clinical association between diabetes mellitus and hypertension.

show abstract

Captopril enhances insulin responsiveness of forearm muscle tissue in non‐insulin‐dependent diabetes mellitus

Cited by 143 publications

References 46 publications

Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin Secretion

Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin Secretion

Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study

The multi‐faceted cross‐talk between the insulin and angiotensin II signaling systems

Contact Info

Product

Resources

About